Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort
- 20 July 2023
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 98 (10) , E285-E287
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesBlood, 2021
- A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitorsBlood, 2019
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studyThe Lancet Haematology, 2019
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012